drugset / Trial / NCT07477743

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

NCT07477743

Phase 1 Recruiting 331 enrolled HC Biopharma Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced gastrointestinal cancer and determine the recommended dose for subsequent studies.

Timeline

Start
2026-03-17
Primary completion
2027-12-31
Completion
2028-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule
Subject HC006 Monoclonal antibody Intravenous
Subject HC010 Unknown Intravenous
Subject Oxaliplatin Small molecule
Subject Paclitaxel Small molecule

Indications

No indication recorded.